Update information

October 2018: The recommendations and section 2 were updated because the marketing authorisation for eltrombopag now includes people who have not had a splenectomy.

April 2017: The company changed from GlaxoSmithKline to Novartis. Contact details for the patient access scheme updated.

Minor changes since publication

January 2023: The title of this guidance was updated and the term 'immune (idiopathic) thrombocytopenic purpura' was changed to 'immune thrombocytopenia' throughout.

ISBN 978-1-4731-0236-1

  • National Institute for Health and Care Excellence (NICE)